Skip to main content
TARS
NASDAQ Life Sciences

Tarsus Closes $450M Alkeus Acquisition, Adds Phase 3 Stargardt Asset

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$81.12
Mkt Cap
$3.56B
52W Low
$48.2
52W High
$91.53
52W Position info
68% above low
Off High info
11% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

TARS sits 68% above its 52-week low of $48.2.

Summary

Tarsus closed its acquisition of Alkeus Pharmaceuticals, adding the Phase 3 Stargardt disease candidate gildeuretinol (ALK-001) to its pipeline. The deal involved $270 million in cash, 2.9 million shares of stock, and up to $350 million in milestone payments.


Key Events · M&A and Partnerships · TARS

  • Alkeus Acquisition Completed

    The acquisition of Alkeus Pharmaceuticals closed on September 4, 2026, with Tarsus paying $270 million in cash and issuing 2,908,692 shares of common stock valued at $180 million.

  • Phase 3 Stargardt Asset Added

    The deal adds gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease with Breakthrough Therapy, Orphan Drug, Fast Track, and Rare Pediatric Disease designations. Topline data from the NORTHSTAR trial is anticipated in 2029.

  • Contingent Consideration Structure

    Up to $350 million in milestone payments: $250 million upon U.S. regulatory approval (payable in cash and/or stock) and $100 million upon first commercial sale in the U.S., plus tiered royalties in the low-to-mid single digits on future worldwide gildeuretinol sales.

  • Registration Rights Effective

    The registration rights agreement and joinder/lock-up agreements with Alkeus equityholders became effective upon closing, providing resale registration rights for the newly issued shares.


Analysis · TARS · Life Sciences

The acquisition of Alkeus Pharmaceuticals closed on September 4, 2026, with Tarsus paying $270 million in cash and issuing 2,908,692 shares of common stock, valued at $180 million based on the $61.38 per-share reference price in the merger agreement. This brings gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease with no FDA-approved treatment, into Tarsus's eye care pipeline. The filing also quantifies the contingent consideration: up to $350 million in milestone payments tied to U.S. regulatory approval and first commercial sale, plus tiered royalties on future worldwide sales. For a company with a $3.56 billion market cap, this is a significant strategic expansion, adding a potential blockbuster asset in a large inherited retinal disease market.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TARS was trading at $81.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $48.20 to $91.53. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TARS - Latest Insights

TARS
Nov 03, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $74.00
Real-time Price: $78.20 info
Change: +$4.20 (+6%) info
Market Cap: $3.856B info
TARS
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $71.24
Real-time Price: $78.20 info
Change: +$6.96 (+10%) info
Market Cap: $3.856B info
TARS
Oct 13, 2026, 4:00 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $70.82
Real-time Price: $78.20 info
Change: +$7.38 (+10%) info
Market Cap: $3.856B info
TARS
Aug 06, 2026, 7:25 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $58.27
Real-time Price: $78.20 info
Change: +$19.93 (+34%) info
Market Cap: $3.856B info
TARS
Aug 06, 2026, 7:23 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $58.27
Real-time Price: $78.20 info
Change: +$19.93 (+34%) info
Market Cap: $3.856B info